111In-octreotide scintigraphy in pituitary adenomas.

A. Tofani, R. Cucchi, A. Pompili, C. Carapella, M. Crecco, M. Mottolese, C. L. Maini

Research output: Contribution to journalArticlepeer-review


This study reports on 111In-octreotide scintigraphy in 20 patients affected with pituitary adenomas, including tracer uptake ratios and in vitro immunohistochemical characterization of the matostatin receptor state. 111In-octreotide uptake was already observed at 4 hours in 7/8 GH-secreting adenomas, in 5/7 non-secreting adenomas and in 1/5 prolactinomas. Concordance between the scan and the histochemical results was observed in all cases. The uptake ratios evaluated at 24 hours ranged from 2.3 to 4.2. The following conclusions were drawn: 1) 111In-octreotide is a suitable tracer to evaluate the somatostatin receptor state of pituitary adenomas; 2) Semi-quantitative measures of tracer uptake can be easily obtained with static planar scanning, but more refined techniques are needed for receptor kinetics evaluation; 3) This nuclear technique is a promising non-invasive tool to identify patients with somatostatin receptor positive pituitary adenomas who might potentially benefit from pre- and/or post-surgery cold octreotide medical treatment.

Original languageEnglish
Pages (from-to)94-97
Number of pages4
JournalQuarterly Journal of Nuclear Medicine
Issue number4 Suppl 1
Publication statusPublished - Dec 1995

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of '111In-octreotide scintigraphy in pituitary adenomas.'. Together they form a unique fingerprint.

Cite this